

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Peter Hoskin	Chair (Oncologist)	Indirect, financial	Grants from Varian, Astellas, Bayer, Millenium for trials in prostate cancer paid to department through E&N Herts NHS trust.	Prior to 02/17 Long-standing research activity >20yrs	09/02/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Peter Hoskin	Chair (Oncologist)	Direct, financial	Expenses from American Society for Clinical Oncology (ASCO) for attendance at Annual GU meeting to take part in case discussion sessions in prostate cancer.	2016	09/02/2017	2016	Declare and participate. Rationale: Interest is non-specific. Expenses within the NICE non-staff travel, subsistence and general expenses policy.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Peter Hoskin	Chair (Oncologist)	Direct, financial	Expenses from Royal College of Surgeons of Ireland to attend annual meeting as Visiting Professor delivering lectures on prostate management, brachytherapy and oligometastases.	2016	09/02/2017	2016	Declare and participate. Rationale: Interest is non-specific. Expenses within the NICE non-staff travel, subsistence and general expenses policy.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Peter Hoskin	Chair (Oncologist)	Direct, financial	Expenses from Singapore Radiology Association to attend annual meeting and deliver lectures on radiotherapy quality assurance, brachytherapy and oligometastases.	2016	09/02/2017	2016	Declare and participate. Rationale: Interest is non-specific. Expenses within the NICE non-staff travel, subsistence and general expenses policy.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Peter Hoskin	Chair (Oncologist)	Direct, financial	Expenses from Kolkota Medical Centre funded by Tata Foundation to deliver lecture on cancer management.	2016	09/02/2017	2016	Declare and participate. Rationale: Interest is non-specific. Expenses within the NICE non-staff travel, subsistence and general expenses policy.
Peter Hoskin	Chair (Oncologist)	Direct, non-financial	Member of Council Royal College of Radiologists	2015	09/02/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Peter Hoskin	Chair (Oncologist)	Direct, non-financial	Chairman, Clinical Oncology, Fellowship Examining Board Royal College of Radiologists	2014	09/02/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Peter Hoskin	Chair (Oncologist)	Direct, financial	Clinical Editor Radiotherapy & Oncology. Office support expenses received.	2014	09/02/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Peter Hoskin	Chair (Oncologist)	Direct, non-financial	Board member ESTRO (European Society for Radiotherapy & Oncology)	2015	09/02/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Peter Hoskin	Chair (Oncologist)	Direct, non-financial	Member of the Editorial Board, Journal of Contemporary Brachytherapy	2009	09/02/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Peter Hoskin	Chair (Oncologist)	Direct, non-financial	Current Chair of University of Oxford Radiotherapy and Imaging Oversight Committee	Mar 2015	09/02/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Peter Hoskin	Chair (Oncologist)	Direct, non-financial	On the DMEC for nine national multicenter NIHR portfolio trials (Chair for six). No expenses or honorarium received.	Over 20 years	09/02/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Peter Hoskin	Chair (Oncologist)	Direct, financial	Travel reimbursement for academic meetings: University of Manchester, University of Montreal, University of Freiberg, University of Sheffield, ASTRO, ESTRO	2016	27/04/2017	2017	Declare and participate. Rationale: Interest is non-specific. Expenses within the NICE non-staff travel, subsistence and general expenses policy.
Peter Hoskin	Chair (Oncologist)	Direct, non-financial	Board member ESTRO (European Society of Radiotherapy & Oncology)	2015	27/04/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Peter Hoskin	Chair (Oncologist)	Direct, non-financial	Committee member GEC ESTRO (Brachytherapy committee)	2004	27/04/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Peter Hoskin	Chair (Oncologist)	Direct, non-financial	Member of Academic Board ICR (Institute of Cancer Research)	2012	27/04/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Peter Hoskin	Chair (Oncologist)	Direct, non-financial	Member of Weston Park Charity Grants Committee	2012	27/04/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee				Publication Date: 29 January 2020			
Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Peter Hoskin	Chair (Oncologist)	Direct, non-financial	Appointed member of NIHR bladder and renal clinical studies group	Sep 2012	04/04/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Peter Hoskin	Chair (Oncologist)	Direct, financial	Expenses received to attend examinations as an external examiner from University of Colombo.	2003	04/09/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Membership of ACPGBI (The Association of Coloproctology of Great Britain and Ireland), ASCRS (The American Society of Colon and Rectal Surgeons), ESCP (European Society of Coloproctology)	2016	25/02/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Member of the Royal Society of Medicine	2012	25/02/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Fellowship of Royal College of Surgeons of England	2013	25/02/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, financial	Clinical Advisor Check4Cancer Ltd It is a company that provides cancer screening tests, I am a clinical advisor for their bowel cancer screening arm that utilises immunochemical faecal occult blood testing, and I am paid a monthly fee for this.	May 2013	25/02/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific because screening is outside the scope of the guideline.

Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, financial	Educational grants and teaching honoraria from Ethicon EndoSurgery. and Covidien/Medtronic. The last payments were received: Covidien – Sep 2013 Ethicon – early 2016	2013 Early 2016	25/02/2017	2013 Early 2016	Declare and participate. Rationale: Interest is specific as the companies produce medical devices used for minimally invasive procedures for rectal and colon surgeries, and the Topic Advisor provided training for other surgeons on these techniques. The Topic Advisor has not been involved in this activity since 2016 and the last payment was received a
---------------	--	----------------------	--	--------------------	------------	--------------------	--

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
							year before appointment to the guideline committee. This is not considered to pose a conflict for his participation in the committee.
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Clinical Member, Specialist Cancer Surgery Clinical Reference Group since 2016 onwards	2016	25/02/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Steering Group Member and Co-Educational Lead, United Kingdom Transanal TME pilot training programme since 2016 onwards	2016	25/02/2017	Ongoing	Declare and participate. Rationale: Interest is specific to review question about rectal surgery technique, however, the role in this steering group is part of a professional role and relates to training surgeons. This does not include financial gain or interest to promote a particular intervention.
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Education and Training Board Member, Association of Surgeons of Great Britain and Ireland (2013-16)	2013	25/02/2017	2016	Declare and participate.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
							Rationale: Interest is non-specific.
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Association of Surgeons of Great Britain and Ireland/ACPGBI Expert Working Party, Management of Anastomotic Leaks. F D McDermott, S Arora, J Smith, R J C Steele, G L Carlson, D C Winter & on behalf of the ASGBI/ ACPGBI Anastomotic Leak Working Group (including Davies R J.) ASGBI Issues in Professional Practice: Prevention, Diagnosis & Management Of Colorectal Anastomotic Leakage. 2016	2013	25/02/2017	March 2016	Declare and participate. Rationale: Interest is non-specific. Management of anastomotic leak is outside the scope of the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Buczacki S, Davies R J. Complete mesocolic excision (CME) with central vessel ligation (CVL): a new standard in colon cancer surgery (editorial) Translational Gastrointestinal Cancer 2015; 4: 182-184	2015	25/02/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific as the techniques covered in this editorial are outside the scope of the guideline.
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Buczacki S, Davies R J. The confounding effects of tumour heterogeneity and cellular plasticity on personalised surgical management of colorectal cancer Colorectal Disease 2014; 16: 329-331	2014	25/02/2017	Ongoing	Declare and participate. Rationale: The interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Buczacki S, Davies R J Colon resection- is standard technique adequate? Surgical Oncology Clinics of North America 2014; 23: 25-34	2014	25/02/2017	Ongoing	Declare and participate Rationale: The interest is non-specific as technique of colon resection is outside the scope of the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Pantelides N M, Davies R J, Fearnhead N S, Malata C M. The gluteal fold flap: a versatile option for perineal reconstruction following anorectal cancer resection. Journal of Plastic, Reconstructive and Aesthetic Surgery 2013; 66: 812-820	2013	25/02/2017	Ongoing	Declare and participate Rationale: Interest is non-specific as perineal reconstruction is outside the scope of the guideline.
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Buczacki S, Davies R J, Winton D J. Stem cells, quiescence and rectal carcinomas: an unexplored relationship and potential therapeutic target. British Journal of Cancer 2011; 105: 1253-1259	2011	25/02/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific

Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Alvi A, Wood L, Davies R J. A selective policy ensures safe integration of laparoscopic colorectal resection into the practice of a newly appointed consultant surgeon. Open Colorectal Cancer Journal 2009; 2: 7-10	2009	25/02/2017	Ongoing	Declare and participate. Rationale: This paper relates to the process of integrating laparoscopic approach to colorectal surgery practice. While it relates to the review question on surgical technique for rectal cancer it does not convey opinions on the matter or study the effectiveness of the technique.
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Davies R J, Barros D'Sa I, Lucarotti M E, Fowler A L, Tottle A, Birch P, Cook T A.	2005	25/02/2017	Ongoing	Declare and participate. Rationale: This paper

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
			Bowel function following insertion of self-expanding metallic stents for palliation of colorectal cancer. Colorectal Disease 2005; 7: 251-253				did not feature as evidence in the guideline.
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Davies R J, Miller R, Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nature Reviews Cancer 2005; 5: 199-209	2005	25/02/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific because screening is outside the scope of the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Davies R J, Collins C D, Vickery C J, Eyre-Brook I, Welbourn R. Reduction in the proportion of patients with colorectal cancer presenting as an emergency following the introduction of fast-track flexible sigmoidoscopy: a three-year prospective observational study. Colorectal Disease 2004; 6: 265-267	2004	25/02/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific because diagnosis is outside the scope of the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	<p>Scott I S, Morris L S, Bird K, Davies R J, Vowler S L, Rushbrook S M, Marshall A E, Laskey R A, Miller R, Arends M J, Coleman N.</p> <p>A novel immunohistochemical method to estimate cell cycle phase distribution in archival tissue: implications for the prediction of outcome in colorectal cancer.</p> <p>Journal of Pathology 2003; 201: 187-197</p>	2003	25/02/2017	Ongoing	<p>Declare and participate.</p> <p>Rationale: Interest is non-specific because the topic is outside the scope of the guideline.</p>

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Davies R J, Freeman A, Morris L, Bingham S, Dilworth S, Scott I S, Laskey R, Miller R, Coleman N. Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet 2002; 359: 1917-1919	2002	25/02/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific because screening/diagnosis is outside the scope of the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Member of International Pelvic Exenteration Collaborative Group (Pelvex)	2015	15/11/2017	Ongoing	<p>Declare and participate.</p> <p>Rationale: Interest is specific to review question about pelvic exenteration, however, this is a professional component of the member's role and there is no financial gain related to the topics under discussion.</p>

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, financial	<p>I undertake private practice at Cambridge Nuffield, Spire Cambridge Lea and Addenbrooke's Hospital, Cambridge, treating patients with all colorectal conditions, including those with colorectal cancer.</p> <p>My private practice entirely mirrors my NHS practice, and I diagnose and treat patients with colorectal cancer in NHS and private practice as part of a MDT. As is the norm, I receive payment for my private practice, as I do for my NHS practice.</p> <p>Paid on a 'fee per service' basis.</p> <p>Justin estimated that about 5% of the colorectal cancer patients he sees are private and 95% are with the NHS. Private patients and NHS patients are treated identically.</p>	2007	22/11/2017 and 28/03/2018	Ongoing	<p>Declare and participate.</p> <p>Rationale: Private practice mirrors entirely his NHS practice and constitutes only 5% of his colorectal patients.</p>

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Pelvex Collaborative. Surgical and survival outcomes following pelvic exenteration for locally advanced rectal cancer: Results from an international collaboration. Annals of Surgery 2017 Sep 21. doi: 10.1097/SLA.0000000000002528. [Epub ahead of print]	2017	04/04/2018	Ongoing	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Pelvex Collaborative. Factors affecting the outcomes following pelvic exenteration for locally recurrent rectal cancer: Results from an international collaboration. British Journal of Surgery 2018 Mar 12. doi: 10.1002/bjs.10734. [Epub ahead of print]	2018	04/04/2018	Ongoing	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Xanthis A, Greenberg D, Miller R. Fearnhead N, Davies R J, Hall N. Local recurrence after 'standard' abdominoperineal resection: do we really need ELAPE? Annals of The Royal College of Surgeons of England 2017; (in press)	2017	04/04/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific because the topic is outside the scope of the guideline.
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Royal Society of Medicine Section of Coloproctology Council Member. Various roles undertaken including council member, vice-president and international representative, previous Honorary Secretary.	2012	18/06/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Tripartite 2020 International consensus on low anterior resection syndrome (contributing member)	May 2018	20/06/2018	Ongoing	Declare and participate. Rationale: This consensus group work relates to defining LARS and does not relate to the treatments of LARS (which is covered by this guideline).

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Member of the IBD Committee (ASCRS)	July 2018	18/12/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Member of the UK National Reproductive ESCP (European Society of Coloproctology)	Sep 2018	18/12/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, non-financial	Chair of the IBD Committee (ACPABI)	Nov 2018	18/12/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, financial	Chair of scientific session and presentation for Alpine Colorectal Meeting, Switzerland. Registration fee was waived for the meeting.	Jan 2019	14/02/2019	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Justin Davies	Topic Advisor (Colorectal Surgeon)	Direct, financial	Examiner –European Board of Surgery Qualification (EBSQ) in Coloproctology	May 2013	24/04/2019	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Julie Hepburn	Committee Lay Member	Direct and indirect, financial	Co-applicant and member of Trial Management Group for RAMAN Trial (RAMAN Spectroscopy and Colorectal Cancer: Towards Early Diagnosis and Personalised Medicine). Honoraria paid	29/06/2017	06/10/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific as diagnosis is outside the scope of the guideline.

Julie Hepburn	Committee Lay Member	Direct, financial	Member of Trial Management Group for PARIS (Physiotherapy and Anterior resection Syndrome) Honoraria paid	29/09/2015	06/10/2017	Ongoing	Declare and participate. Rationale: Interest relates to the review on management of LARS, however, the trial is an on-going single-arm study and has not published any results yet and for these reasons was not of interest to the review. Julie's involvement relates to her interest in colorectal cancer research from a patient perspective.
Julie Hepburn	Committee Lay Member	Direct, financial	Member of Trial Management Group for HART (Hughes Abdominal Repair Trial)	02/02/2016	06/10/2017	02/11/2018	Declare and participate.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
			Honoraria paid				Rationale: Interest is non-specific and outside the scope of the guideline.
Julie Hepburn	Committee Lay Member	Direct, financial	Member of Steering Group for HART (Hughes Abdominal Repair Trial) Honoraria paid	02/11/2018	02/11/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific and outside the scope of the guideline.

Julie Hepburn	Committee Lay Member	Direct, financial	Member of Steering Committee for SAILOR (Multicentre Randomised Feasibility Trial evaluating Early Surgery Alone in Low Rectal Cancer) Honoraria paid	15/10/2018	06/10/2017	Ongoing	Declare and participate. Rationale: Interest relates to the review question about preoperative radiotherapy or chemoradiotherapy for rectal cancer. The trial is on-going and has not published any results. Julie's involvement relates to her interest in colorectal cancer research from a patient perspective.
Julie Hepburn	Committee Lay Member	Direct, financial	Member of Trial Management Group for ABACus (Awareness and Beliefs about Cancer)	06/12/2016	06/10/2017	Ongoing	Declare and participate.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
			Honoraria paid				Rationale: Interest is non-specific.
Julie Hepburn	Committee Lay Member	Direct, financial	Research Partner for the Wales Cancer Research Centre Honoraria paid	01/06/2016	06/10/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Julie Hepburn	Committee Lay Member	Direct, financial	Member of Steering Committee and Trial review Group for Centre for Trials Research – Cancer Group University of Cardiff. Honoraria paid	21/12/2015	06/10/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Julie Hepburn	Committee Lay Member	Direct, non-financial	Research Partner for Macmillan Horizons Project. No mention of financial interest so far. Likely to involve giving feedback on reports/questionnaires/ web pages etc. Will not be published in the lifetime of Guideline committee.	29/10/2017	18/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Julie Hepburn	Committee Lay Member	Direct and indirect, financial	Co-applicant on the NIPPI Trial. "Quality of recover and avoidance of perioperative hypothermia in people undergoing elective colectomy: a patient-blinded randomized controlled trial comparing the HumiGard insufflation device to UK standard care". Currently applying for funding. Will not publish within the lifetime of the Guideline Committee. Honorarium paid.	03/10/2017	18/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific and outside the scope of the guideline.

Julie Hepburn	Committee Lay Member	Direct, financial	Honorarium for reviewing Patient Documentation on LARRIS Trial	15/09/2015	08/06/2018	Ongoing	<p>Declare and participate.</p> <p>Rationale: Interest is relates to the review on management of LARS, however, no publications from the LARRIS study were included in the review. Julie's involvement in the trial relates to her interest in colorectal cancer research from a patient perspective.</p>
Julie Hepburn	Committee Lay Member	Direct, financial	Member of Trial Management Group for CRaFT (Combined RAMAN-FIT testing for CRC). Honorarium paid.	20/12/2018	14/02/2019	Ongoing	<p>Declare and participate.</p> <p>Rationale: Interest is non-specific</p>

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
							because screening/diagnosis is outside the scope of the guideline.
Julie Hepburn	Committee Lay Member	Direct, financial	Member of Project Team for Chronic Cancer Pain research (PhD Project UWE). Honorarium paid.	14/01/2019	14/02/2019	Ongoing	Declare and participate. Rationale: Interest is non-specific and outside the scope of the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Debby Lennard	Committee Lay Member	Direct, financial	Director of DLConsulting Services The company offered IT services, and Debby was Director, the company has now been closed down. Not specific to CRC.	Dec 2016	06/10/2017	April 2018	Declare and participate. Rationale: Interest is non-specific.
Debby Lennard	Committee Lay Member	Indirect, non-financial	Programme Manager Help-Digital Community of Interest Company (CIC). Not specific to CRC.	Apr 2016	06/10/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Debby Lennard	Committee Lay Member	Direct, financial	Lay member Research for Patient Benefit NIHR Board Expenses and honoraria paid.	Oct 2015	06/10/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Debby Lennard	Committee Lay Member	Direct, financial	CR-UK Cancer Intelligence Working Group Expenses and honorarium paid.	Oct 2017	17/11/2017	August 2018	Declare and participate. Rationale: Interest is non-specific.
Debby Lennard	Committee Lay Member	Direct, financial	CR-UK Research and Innovation Sounding Board Expenses and honorarium paid.	Sep 2015	17/11/2017	February 2018	Declare and participate. Rationale: Interest is non-specific.
Debby Lennard	Committee Lay Member	Direct, financial	CR-UK Grand Challenge Patient Review Panel Expenses and honorarium paid.	Nov 2017	17/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Debby Lennard	Committee Lay Member	Direct, financial	Macmillan funded research project looking at GP/ Patient conversation (co-applicant) Expenses and honorarium paid.	Apr 2017	17/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Debby Lennard	Committee Lay Member	Direct and indirect, financial	UCL research project Living with OG Cancer (co-applicant) Expenses and honorarium paid.	Oct 2017	17/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Debby Lennard	Committee Lay Member	Direct, financial	Fast Assessment and Treatment Healthcare Network Advisory Group (UCL project) Expenses and honorarium paid.	April 2017	17/11/2017	On-going	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Debby Lennard	Committee Lay Member	Direct, financial	Francis Report Implementation Review Project Advisory Group Expenses and honorarium paid.	May 2014	17/11/2017	September 2018	Declare and participate. Rationale: Interest is non-specific.
Debby Lennard	Committee Lay Member	Direct, financial	NETSCC Patient Referral Group (NIHR Evaluation, Trials and Studies Coordinating Centre) Expenses and honorarium paid.	2015	17/11/2017	On-going	Declare and participate. Rationale: Interest is non-specific.
Debby Lennard	Committee Lay Member	Direct, financial	Lay member on the research for NIHR Public Benefit Social Care Board. Role started in May 2018. Expenses and honorarium paid.	May 2018	03/05/2018	December 2018	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Baljit Singh	Committee member (Colorectal Surgeon)	Indirect, financial	Industry funded (LifeCell Corporation) 2012-2014 (£116, 470 – paid to Department). Research grant paid to Department and speaker for LifeCell. This was a research study about the use of biological mesh, not related to CRC. Expenses and honorarium paid.	2012	04/09/2017	2017	Declare and participate. Rationale: Interest is non-specific.
Baljit Singh	Committee member (Colorectal Surgeon)	Indirect, financial	Principal Investigator. Perineal wound reconstruction and simultaneous stoma reinforcement using strattice biological mesh following extralevator abdominal perineal excision of rectum (eLAPE). Paid to Department.	2012	04/09/2017	2014	Declare and participate. Rationale: The topic of the trial was outside the scope of the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Baljit Singh	Committee member (Colorectal Surgeon)	Indirect, financial	Co-investigator. MicroRNAs based blood assay for early detection of colorectal cancer. BDRF-Association of Coloproctology of Great Britain and Ireland 2010-12 (£30k)	2010	04/09/2017	2012	Declare and participate. Rationale: Interest is non-specific and outside the scope of the guideline.
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, financial	Recipient of Pump-priming award for newly appointed Consultants and Senior lecturers. The Royal College of Surgeons of England 2010-2011 (£10k)	2010	04/09/2017	2011	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Baljit Singh	Committee member (Colorectal Surgeon)	Indirect, financial	Principal Investigator. Quantitative analysis of DNA extracted from the rectal mucosa of patients with colorectal disease. Industry funded, Origin Sciences Ltd 2010-11 (£20k paid to Department) Colorectal disease include: colorectal cancer and also benign conditions such as inflammatory bowel disease and diverticular disease.	2010	04/09/2017	2011	Declare and participate. Rationale: Interest is non-specific and outside the scope of the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Member of the NHS England FIT pioneer group and lead for the FIT working group in ACPGBI	Apr 2018	18/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific because screening is outside the scope of the guideline.
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Reviewer for British Journal of Surgery, World Journal of Surgery and Techniques in Coloproctology	2013	18/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Expert Adviser for the NICE Centre for Guidelines including expert commentary for NICE on New Technologies (Permacol paste and VAAFT)	2017	18/11/2017	2020	Declare and participate. Rationale: Interest is non-specific.
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Involved in implementing Faecal immunochemical testing in the East Midlands	Jan 2018	18/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Director of the Scientific Committee of the Association of Surgeon GB&I (ASGBI) 2013-to date.	2013	18/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Treasurer Association of Coloproctology GB&I (ACPGBI) 2014-17 and Executive member of the ACPGBI.	2014	18/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Member of the Research and Audit Committee ACPGBI 2010-2016.	2010	18/11/2017	2016	Declare and participate. Rationale: Interest is non-specific.
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Member of the National Bowel Cancer Audit (NBOCA) Clinical Advisory Group 2014-to date.	2014	18/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Member of Council Coloproctology Section, Royal Society of Medicine (RSM) 2013-to date and Treasurer 2014-to date.	2013	18/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Member of the Education Committee European Society of Coloproctology (ESCP) 2013-to date.	2013	18/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Member of the ESCP Cohort Studies Group 2014-to date.	2014	18/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Member of the New Technology Committee American Society of Colorectal Surgeons (ASCRS) 2014-to date.	2014	18/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	CRN East Midlands Colorectal Cancer Specialty Lead 2014-date.	2014	18/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	CRN East Midlands Colorectal Specialty Lead 2016-date.	2016	18/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Member of the Surgical Speciality Group National Institute of Health Research (NIHR).	2013	18/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Member of the Dr Foster GI GOAL collaborative.	2015	18/11/2017	Nov 2017	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, financial	Private practice with privileges at Spire and Nuffield Hospitals Leicester since 2010. I see patients at most once a monthly with Colorectal problems ie clinic Payment is received if a patient is seen. Paid on a 'fee per service' basis. Private practice is identical to NHS practice. Has a very small private practice workload. He saw 3 patients privately in the last year and estimates that it accounts for about 1% of his workload.	2010	23/11/2018 and 28/03/2018	Ongoing	Declare and participate. Rationale: Private practice mirrors entirely his NHS practice and constitutes only 1% of his workload.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Widlak MM, Thomas CL, Thomas MG, Tomkins C, Smith S, O'Connell N, Wurie S, Burns L, Harmston C, Evans C, Nwokolo CU, Singh B, Arasaradnam RP. Aliment Pharmacol Ther. Diagnostic accuracy of faecal biomarkers in detecting colorectal cancer and adenoma in symptomatic patients. Aliment Pharmacol Ther. 2017 Jan;45(2):354-363. doi: 10.1111/apt.13865.	2017	14/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific and outside the scope of the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Musters GD, Klaver CE, Bosker RJ, Burger JW, van Duijvendijk P, van Etten B, van Geloven AA, de Graaf EJ, Hoff C, Leijtens JW, Rutten HJ, Singh B, Vuylsteke RJ, de Wilt JH, Dijkgraaf MG, Bemelman WA, Tanis PJ. Biological Mesh Closure of the Pelvic Floor After Extralevator Abdominoperineal Resection for Rectal Cancer: A Multicenter Randomized Controlled Trial (the BIOPEX-study). Ann Surg. 2016 Sep 20 (Epub ahead of print)	2016	14/11/2017	Ongoing	Declare and participate. Rationale: Biological mesh closure is outside the scope of the guideline.
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Patel M, Verma A, Aslam I, Pringle H, Singh B. Novel plasma microRNA biomarkers for the identification of colitis-associated carcinoma. Lancet. 2015 Feb 26;385 Suppl 1:S78. doi: 10.1016/S0140-6736(15)60393-2.	2015	14/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Verma AM, Patel M, Aslam MI, Jameson J, Pringle JH, Wurm P, Singh B. Circulating plasma microRNAs as a screening method for detection of colorectal adenomas. Lancet. 2015 Feb 26;385 Suppl 1:S100. doi: 10.1016/S0140-6736(15)60415-9.	2015	14/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific and outside the scope of the guideline.
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Munasinghe A, Singh B, Mahmoud N, Joy M, Chang DC, Penninckx F, Faiz O. Reduced perioperative death following laparoscopic colorectal resection: results of an international observational study. Surg Endosc. 2015 Mar 12.	2015	14/11/2017	Ongoing	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Aslam MI, Hussein S, West K, Singh B, Jameson JS, Pringle JH. MicroRNAs associated with initiation and progression of colonic polyp: A feasibility study. Int J Surg. 2015 Jan;13:272-9.	2015	14/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Aslam MI, Venkatesh J, Jameson JS, West K, Pringle JH, Singh B. MicroRNA expression profiling based identification of high risk Dukes' Stage B colorectal cancer: a preliminary study. Colorectal Dis. 2014 Dec 30.	2014	14/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific and outside the scope of the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Butt HZ, Salem MK, Vijaynagar B, Chaudhri S, Singh B. Perineal reconstruction after extra-levator abdominoperineal excision (eLAPE): a systematic review. Int J Colorectal Dis. 2013 Nov;28(11):1459-68.	2013	14/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific and outside of the scope of the guideline.
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Aslam MI, Patel M, Singh B, Jameson JS, Pringle JH. MicroRNA manipulation in colorectal cancer cells: from laboratory to clinical application. J Transl Med. 2012 Jun 20;10:128	2012	14/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific and outside of the scope of the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Kelly MJ, Singh B, Jones O, Wilson J, deCaestecker J, Robinson R, Mastermann J, Duckett T, Cook T. MDTs. Resources for Coloproctology. ACPGBI 2015	2015	14/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	B.Singh, C. Cunningham. Surgery for Colorectal Cancer. MDT Approach to Cancer of the Colon and Rectum in GI Oncology-A Critical MDT Approach edited by Jankowski, Sampliner, Kerr and Fong. 2008	2008	14/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	I have been asked to complete a questionnaire on NICE CG49 on whether the guidelines need to be updated. NICE CG49 is related to 'Faecal incontinence in adults: management'.	2018	10/01/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Baljit Singh	Committee member (Colorectal Surgeon)	Direct, non-financial	Chair of the East Midlands Cancer Alliance Group.	01/12/2018	18/12/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	Medical Advisory Board of Bowel Cancer UK (charity)	2012	15/11/2017	Ongoing	<p>Declare and participate.</p> <p>Rationale: The interest is non-financial, the remit of the advisory board is broad and not directly related to the specific topics covered in the guideline. This interest is not considered to influence the recommendations.</p>
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	British Society of Gastroenterology (BSG): member of Colorectal, Cancer and Clinical Standards and Services Committee	2009	15/11/2017	2014	<p>Declare and participate.</p> <p>Rationale: The interest is non-financial, the remit of the committee is broad and</p>

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
							not directly related to the specific topics covered in the guideline. This interest is not considered to influence the recommendations.
Kevin Monahan	Committee member (Gastroenterologist)	Direct, financial	Member of Colo-speed Consortium – UK wide collaborative forum submitting for CRUK Catalyst Award. Honorarium received.	2017	15/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	Publication: Monahan K, Murphy R, O’Gorman T, Headon D. The molecular genetics of colorectal cancer, Irish Journal of Medical Science, April S1, 1995.	1995	15/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	The molecular genetics of colorectal cancer and a family with an unusual inherited phenotype (BSc Thesis)	1995	15/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	Medipaedia (doctors.net.org review articles) (1) Lifestyle and colorectal cancer risk; (2) Inflammatory bowel disease and colorectal cancer risk; (3) Hereditary colorectal cancer syndromes.	2006	15/11/2017		Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	New genes for inherited multiple polyps and cancers of the large bowel (PhD Thesis)	2010	15/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	Maria Adelson, Samuel Pannick, James E East, Peter Risby, Peter Dawson, Kevin J Monahan. UK colorectal cancer patients are inadequately assessed for Lynch syndrome. Frontline Gastroenterology Jan 2014	2014	15/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific, assessment for Lynch syndrome is not in the scope of this guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	Kevin J Monahan, Susan K Clark, on behalf of the British Society of Gastroenterology (BSG) Cancer Group. A national survey of hereditary colorectal cancer services in the UK. Frontline Gastroenterology April 2014	2014	15/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	Yusuf A, Monahan KJ, 2014, Genetics for Health Professionals in Cancer Care: From Principles to Practice(Chapter 19: Early detection of hereditary colorectal and gastric cancer), Genetics for Health Professionals in Cancer Care: From Principles to Practice, Editors: Jacobs, Robinson, Webb, Publisher: Oxford University Press, Pages: 165-172, ISBN: 9780191653483	2014	15/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	Kaur A, Monahan KJ, Schofield J, Lishman S, Alsina D, Bason Net al., PWE-346 Lynch syndrome and application of the rcpath colorectal cancer dataset in the united kingdom, <i>Gut</i> , Vol: 64, Pages: A362.1-A362, 2015, ISSN: 0017-5749.	2015	15/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	Monahan KJ, Hopkins L. Diagnosis and Management of Hereditary Gastric Cancer., <i>Recent Results Cancer Res</i> , Vol:205, 2016, ISSN:0080-0015, Pages:45-60	2016	15/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	Aggarwal N, Donald ND, Malik S, Selvendran SS, McPhail MJW, Monahan KJ, Aggarwal N, Donald ND, Malik S, Selvendran SS, McPhail MJ, Monahan KJ. The Association of Low-Penetrance Variants in DNA Repair Genes with Colorectal Cancer: A Systematic Review and Meta-Analysis. Clinical And Translational Gastroenterology, Vol: 8, ISSN: 2155-384X (published 2017)	2017	15/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	Donald N, Malik S, McGuire JL, Monahan KJ, Donald N, Malik S, McGuire JL, Monahan KJ. The association of low penetrance genetic risk modifiers with colorectal cancer in lynch syndrome patients: a systematic review and meta-analysis., Fam Cancer, Pages: 1-10, ISSN: 1389-9600 (published 2017)	2017	15/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	Monahan KJ, Alsina D, Bach S, Buchanan J, Burn J, Clark S, Dawson P, De Souza B, Din FVN, Dolwani S, Dunlop MG, East J, Evans DG, Fearnhead N, Frayling IM, Glynne-Jones R, Hill J, Houlston R, Hull M, Lalloo F, Latchford A, Lishman S, Quirke P, Rees C, Rutter M, Sasieni P, Senapati A, Speake D, Thomas H, Tomlinson I, Urgent improvements needed to diagnose and manage Lynch syndrome, BMJ-BRITISH MEDICAL JOURNAL, Vol: 356, Pages: j1388-j1388, ISSN: 1756-1833 (published 2017)	2017	15/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	Specialist Committee Member on the Diagnostic Advisory Committee for the development of NICE guideline DG27 'Molecular testing strategies for Lynch syndrome in people with colorectal cancer'.	2016	15/11/2017	Feb 2017	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	Lawler M, Alsina D, Adams RA, Anderson AS, Brown G, Fearnhead NS, Fenwick SW, Halloran SP, Hochhauser D, Hull MA, Koelzer VH, McNair AGK, Monahan KJ, Näthke I, Norton C, Novelli MR, Steele RJC, Thomas AL, Wilde LM, Wilson RH, Tomlinson I; Bowel Cancer UK Critical Research Gaps in Colorectal Cancer Initiative. Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut. 2018 Jan;67(1):179-193. doi: 10.1136/gutjnl-2017-315333. Review.	2018	15/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	Malik SS, Lythgoe MP, McPhail M, Monahan KJ. Metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis. Fam Cancer. 2017 Nov 30. doi: 10.1007/s10689-017-0062-2. [Epub ahead of print]	2017	15/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	BMJ letter 'Urgent improvements needed to diagnose and manage Lynch syndrome'. 2017	March 2017	15/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	Response to letter to editor regarding published article – metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis. Lythgoe, M.P., Malik, S.S., McPhail, M. & Monahan, K.J.	2017	18/02/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	On the steering committee for the study PRESERVE (early stages of inception). The study does not have a protocol yet, although it follows on from MINSTREL http://minstrelstudy.co.uk/meet-the-team	2018	22/03/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific and outside the scope of the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	Cavazza A, Radia C, Harlow C, Monahan KJ, An Experience of Implementation and Outcomes of Universal Testing for Lynch Syndrome in the United Kingdom., Colorectal Dis, 2019	2019	03/2019	Ongoing	Declare and participate. Rationale: Interest is non-specific and outside the scope of the guideline.
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	Lythgoe MP, Malik SS, McPhail M, et al., 2018, Response to letter to editor regarding published article metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis, Familial Cancer, Vol:17, ISSN:1389-9600, Pages:545-546	2018	03/2019	Ongoing	Declare and participate. Rationale: Interest is non-specific and outside the scope of the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	Cavazza A, Radia C, Harlow C, Monahan KJ. Experience of the implementation and outcomes of universal testing for Lynch syndrome in the United Kingdom. Colorectal Dis. 2019 Feb 28. doi: 10.1111/codi.14597. [Epub ahead of print]	Feb 2019	24/04/2019	Ongoing	Declare and participate. Rationale: Interest is non-specific and outside the scope of the guideline.
Kevin Monahan	Committee member (Gastroenterologist)	Direct, non-financial	Adams LK, Qiu S, Hunt AK, Monahan KJ. A dedicated high-quality service for the management of patients with an inherited risk of colorectal cancer. Colorectal Dis. 2019 Mar 23. doi: 10.1111/codi.14622. [Epub ahead of print]	March 2019	24/04/2019	Ongoing	Declare and participate. Rationale: Interest is non-specific and outside the scope of the guideline.

Vivek Misra	Committee member (Oncologist)	Direct, financial	<p>Honoraria and consultancy fees from various pharmaceutical companies (Amgen, Eisai, Roche and Pfizer), none of these related to the management of colorectal cancers.</p> <p>2017 December & July: Pfizer. Honorarium and travel: Speaker at a meeting regarding palbociclib in Breast cancer May: Eisai. Honorarium and travel: Steering committee for national meeting (metastatic breast cancer)</p> <p>2016 November: Amgen: Honorarium and travel. Speaker at a meeting regarding denosumab in breast cancer (2 meetings) May: Eisai. Honorarium and travel; Steering committee for national meeting (metastatic breast cancer) October: Teva; Registration fees, accommodation and travel for ESMO Meeting (Month not clear): Roche: consultancy fees for advisory board, and presentation regarding breast cancer treatment</p> <p>2015</p>	2015	10/01/2018	2017	<p>Declare and participate.</p> <p>Rationale: Interest is non-specific.</p>
-------------	----------------------------------	----------------------	---	------	------------	------	---

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
			<p>October: Teva; Registration fees, accommodation and travel for ESMO Meeting</p> <p>December: Amgen: Honorarium and travel. Speaker at a meeting regarding denosumab in breast cancer</p> <p>(Month not clear): Novartis: travel and accommodation costs for breast cancer meeting</p> <p>(Month not clear): Pierre fabre: Advisory board for breast cancer drug.</p> <p>There have been some meetings taking place prior to 2015, but there are the same companies and none of them related to colorectal cancer.</p>				

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Vivek Misra	Committee member (Oncologist)	Indirect, financial	PI for ARISTOTLE Phase III trial at the Christie Manchester. No personal funding received for these trials (NCRI funded trial to Department).	2013	15/11/2017	Ongoing	Declare and participate. Rationale: The trial was not relevant to any of the reviews. As a local principal investigator Vivek had no role in the planning of the trial or did not participate in the analysis of the results.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Vivek Misra	Committee member (Oncologist)	Direct, non-financial	SI for PRAER trial in locally advanced rectal cancer. The Department received funding from a company called Eisai, but the trial is a fully approved trial and again no funding was received by myself.	2017	15/11/2017	Ongoing	Declare and participate. Rationale: The one-arm phase I trial was not relevant for the reviews covered in this guideline.
Vivek Misra	Committee member (Oncologist)	Direct, non-financial	SI for OPERA trial in early rectal cancer. No personal funding was received for these trials (NCRI funded trial to Department).	2018	15/11/2017 and 03/05/2018	Ongoing	Declare and participate. Rationale: The trial was not relevant to any of the reviews.

Vivek Misra	Committee member (Oncologist)	Direct, financial	<p>Private Practice: Breast cancer and Colorectal Cancer specialist. For colorectal cancer, I only treat and give advice regarding radiotherapy and chemo-radiotherapy. I am also the chair of The Christie Private Care Medical Advisory Committee and the Clinical Governance Lead for this organisation. Paid on a 'fee per service' basis.</p> <p>Vivek's private practice patients are treated the same as NHS patients. His private work is with the Christie which has the same treatment guideline for private and NHS patients. It is also monitored by the GMC to confirm that it mirrors NHS practice completely. Also does a very small amount of private work. He treated one colorectal cancer patient privately in the last year (compared to 180 patients treated in the NHS).</p>	2008	24/11/2017 and 28/03/2018	Ongoing	<p>Declare and participate.</p> <p>Rationale: Private practice mirrors entirely his NHS practice and constitutes only 0.5% of his colorectal patients.</p>
Vivek Misra	Committee member (Oncologist)	Direct, non-financial	N Ghosal, V Misra, A case of Capecitabine-induced Hyperpigmentation and Radiation Recall Phenomenon, Clinical Oncology 2009 21:632-638	2009	15/11/2017	Ongoing	<p>Declare and participate.</p> <p>Rationale: Interest is non-specific.</p>
Vivek Misra	Committee member (Oncologist)	Direct, non-financial	G Barnett, V Misra et al: Validation study of SNPs to predict Radiation Toxicity (RAPPER Study). Lancet Oncology (2011)	2011	15/11/2017	Ongoing	Declare and participate.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
							Rationale: Interest is non-specific.
Vivek Misra	Committee member (Oncologist)	Direct, non-financial	Barnett, Misra et al: A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity: Radiotherapy and Oncology, 2014	2014	15/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Vivek Misra	Committee member (Oncologist)	Direct, non-financial	J King, V Misra et al: A review of grade 3 bowel toxicity in patients treated with chemoradiotherapy for rectal cancer. Presented at ESTRO 2016.	2016	15/11/2017	Ongoing	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Vivek Misra	Committee member (Oncologist)	Direct, non-financial	Gave a lecture on International controversies in rectal cancer which was organised by ICENI.	12/12/2018	18/12/2018	13/12/2018	Declare and participate. Rationale: Interest is non-specific.

Vivek Misra	Committee member (Oncologist)	Direct, financial	<p>Presentation of The Christie rectal contact radiotherapy outcomes data to the GEC ESTRO/ICONE meeting in Milan.</p> <p>Travel and accommodation paid for from the study budget at The Christie.</p>	29/04/2019	24/04/2019	29/04/2019	<p>Declare and participate.</p> <p>Rationale: Interest is not considered to pose a conflict even though it relates to a topic in the guideline. The member presented the patient outcomes at his hospital to a professional group as part of his professional role and does not include financial gain. Travel and accommodation within the NICE non-staff travel, subsistence and general</p>
-------------	----------------------------------	----------------------	--	------------	------------	------------	--

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee				Publication Date: 29 January 2020			
Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
							expenses policy.
Jayshree Bradbury	Committee member (Specialist Nurse)	Direct, non-financial	Chair of Association of Coloproctology Nursing, subsidiary of Association of Coloproctology of Great Britain and Ireland.	May 2017	20/10/2017	July 2018	Declare and participate. Rationale: Interest is non-specific.
Jayshree Bradbury	Committee member (Specialist Nurse)	Direct, non-financial	Provide specialist nursing input for the national cancer peer review programme. Relates to an NHS programme of standards review in colorectal cancer nationwide. I would visit other hospitals with other clinician and review their standards. I wasn't paid for this, but this was all done under remit of NHS and cancer standards.	2012	20/10/2017	Feb 2016	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Jayshree Bradbury	Committee member (Specialist Nurse)	Direct, non-financial	Member of Association of Stoma Care Nursing UK.	2014	20/10/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Jayshree Bradbury	Committee member (Specialist Nurse)	Indirect, financial	My team are part funded by a stoma company – Salts Healthcare. We all remain NHS employed and have no expectations to use their products. They do help financially with travel and accommodation costs to various conferences but this is within the contract that I have with them that they provide this support.	2014	27/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Jayshree Bradbury	Committee member (Specialist Nurse)	Indirect, financial	I don't undertake any private practice. I do see private patients in the NHS hospitals, but the income goes directly to the Trust.	2014	22/11/2017	Ongoing	Declare and participate. Rationale: The committee member does not undertake private practice although she sees private patients as part of her regular work but does not get remunerated for this beyond her normal salary.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Trustee – Bowel Cancer UK (2016 to present). Non-remunerated.	2016	17/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Stephen Fenwick	Co-opted committee member	Direct, non-financial	Honorary Treasurer of the Association of Upper Gastrointestinal Surgeons – 2015 to present	2015	17/11/2017	Ongoing	Declare and participate.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
	(Hepatobiliary surgeon)						Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, financial	<p>Participation in 3 advisory boards for IPSEN, regarding treatment of neuroendocrine tumours (travel, accommodation and an honorarium paid)</p> <p>The dates for advisory boards are:</p> <p>Wed 28th Sep 2016, Royal College of Practitioners, London</p> <p>Wed 21st Dec 2016, Royal College of Practitioners, London.</p> <p>Wed 8th March 2017, Hilton Hotel, Manchester</p>	2016	17/11/2017	2017	<p>Declare and participate.</p> <p>Rationale: Interest is non-specific.</p>

Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, financial	Chemosaturation Experts Forum Meeting on hepatic perfusional therapies in Prague. Sponsored attendance (Delcath Systems Inc.)	Nov 2017	17/11/2017	Nov 2017	Declare and withdraw from discussions on recommendations relating to chemosaturation until November 2018. Rationale: Chemosaturation relates to question about treatments for metastatic CRC in the liver.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, financial	Sponsored attendance (travel and accommodation) at meeting on electrosurgical instruments (BOWA LOTUS)	Sep 2017	17/11/2017	Sep 2017	Declare and participate. Rationale: Interest is non-specific.
Stephen Fenwick	Co-opted committee member	Direct, financial	Private medical practice with admitting rights at the Sefton Suite Hospital, Liverpool – specialising in Hepatobiliary and General Surgery.	2008	22/11/2017 and 28/03/2018	Ongoing	Declare and participate.

	(Hepatobiliary surgeon)		<p>Payment is received for private practice – either directly funded by the patient or, more often, from insurance companies.</p> <p>The scope of the private practice mirrors the NHS practice. Hepatobiliary and General Surgical procedures are performed/ In both NHS and private practice, liver resections for metastatic colorectal cancer are performed.</p> <p>Paid on a 'fee per service' basis.</p> <p>Private practice patients are treated in the same way as NHS patients. Also a very small private practice caseload – he saw 2 patients privately in the last year compared to 70 in the NHS.</p>				<p>Rationale: Private practice mirrors entirely his NHS practice and constitutes only 3% of his patients.</p>
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, financial	<p>Medicolegal practice – practising as an expert in general surgery and hepatobiliary surgery.</p> <p>Payment is received from instructing solicitors. The scope of this medicolegal practice is confined wholly to those areas of his clinical expertise. All payments are on a fee per service basis.</p>	2016	22/11/2017	Ongoing	<p>Declare and participate.</p> <p>Rationale: No potential to benefit from involvement in the guideline as</p>

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
							a result of this interest (interest is undertaken infrequently and expert advice are used in legal cases which are unlikely to directly impact clinical practice).
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Cyclooxygenase-2 Inhibition in Colorectal Cancer Liver Metastases. 2005. Thesis Degree of Doctor of Medicine, University of Leeds	2005	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Hull MA, Fenwick SW, Chapple KS, Scott N, Toogood GJ, Lodge JP. Cyclooxygenase- 2 expression in colorectal cancer liver metastases. <i>J Clin Exp Metastases</i> 2000; 18: 21	2000	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Fenwick SW, Toogood GJ, Lodge JP, Hull MA. The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. <i>Gastroenterol.</i> 2003; 125: 716-729.	2003	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Fenwick SW, Wyatt JI, Toogood GJ, Lodge JP. Hepatic resection and transplantation for primary carcinoid tumors of the liver. <i>Ann Surg</i> 2004; 239: 210- 219	2004	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Lodge JP, Menon KV, Fenwick SW, Prasad KR, Toogood GJ. In-contiguity and non- anatomical extension of right hepatic trisectionectomy for liver metastases. <i>Br J Surg</i> 2005; 92: 340-347.	2005	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Chalmers CR, Fenwick SW, Toogood GJ, Hull MA. Immunohistochemical measurement of endothelial cell apoptosis and proliferation in formalin-fixed, paraffin-embedded human cancer tissue. <i>Angiogenesis</i> . 2006; 9:193-200	2006	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Nishio H, Hamady ZZ, Malik HZ, Fenwick S, Rajendra Prasad K, Toogood GJ, Lodge JP. Outcome following repeat liver resection for colorectal liver metastases. <i>Eur. J. Surg. Oncol.</i> 2007; 33: 729-34.	2007	22/11/2017	Ongoing	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Malik HZ, Fenwick SW, Poston GJ Colorectal liver metastases. Gastrointestinal <i>Cancer Abstracts.</i> 2009; 24: 2-6	2009	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	G. Sarno, H.Z. Malik, S.W. Fenwick, A. Al-Sarira, G.J. Poston. Retrohepatic Vena Cava resection with right trisectionectomy and caudate lobectomy colorectal liver metastases. <i>Ann Surg Oncol</i> 2010; 17(12): 3162	2010	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Pathak S, Jones R, Tang JM, Parmar C, Fenwick S, Malik H, Poston G. Ablative therapies for colorectal liver metastases (CRLM); a systematic review. <i>Colorectal Disease</i> . 2011; 13(9); 252-65.	2011	22/11/2017	Ongoing	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Jones RP, Kitteringham NR, Terlizzo M, Hancock C, Dunne D, Fenwick SW, Poston GJ, Ghaneh P, Malik HZ. Microwave ablation of ex vivo human liver and colorectal liver metastases with a novel 14.5 GHz generator". <i>Int J Hyperthermia</i> 2012; 28(1): 43-54.	2012	22/11/2017	Ongoing	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Jones RP, Jackson R, Dunne DF, Malik HZ, Fenwick SW, Poston GJ, Ghaneh P. Systematic review and meta-analysis Follow up after hepatectomy for colorectal liver metastases. <i>Br J Surg</i> 2012; 99(4); 477-486.	2012	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Jones RP, Vauthey JN, Adam R, Rees M, Berry D, Jackson R, Grimes N, Fenwick SW, Poston GJ, Malik HZ. Effect of specialist decision-making on treatment strategies for colorectal liver metastases. <i>Br J Surg.</i> 2012; 99 (9):1263-9.	2012	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Dunne, D., Jones, R.P., Malik, H.Z., Fenwick, S.W., White, D., Poston, G.J. Biopsy is not appropriate for incidentally detected liver lesions. <i>British Medical Journal</i> 2012; 344: e2559	2012	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Jones, R.P., Dunne, D.F., Malik, H.Z., Fenwick, S.W., Poston, G.J. Multidisciplinary management of metastatic colorectal cancer; a UK perspective. <i>Taiwanese Journal of Coloproctology</i> 2012; 3:38-43	2012	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Robert P. Jones, Declan Dunn, Paul Sutton, Hassan Z. Malik, Stephen W. Fenwick, Monica Terlizzo, Elizabeth O'Grady, Claus Kölblinger, Stefan Stremitzer, Thomas Gruenberger, Graeme J. Poston. Segmental and lobar administration of DEBIRI-TACE leads to tumour destruction: a case-control series. <i>HPB</i> 2013; 15(1):71-7.	2013	22/11/2017	Ongoing	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Jones RP, Malik HZ, Fenwick SW, Poston GJ. Perioperative chemotherapy for resectable colorectal liver metastases; where now? <i>Eur J Surg Oncol.</i> 2013;39(8):807- 811	2013	22/11/2017	Ongoing	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	de Rosa A, Gomez D, Hossaini S, Duke K, Fenwick SW, Brooks A, Poston GJ, Malik HZ, Cameron IC. Stage IV colorectal cancer – outcomes following the liver-first approach. <i>Eur J Surg Oncol.</i> 2013;108(7):444-9.	2013	22/11/2017	Ongoing	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Dunne DF, Gaughran J, Jones RP, McWhirter D, Sutton PA, Malik HZ, Poston GJ, Fenwick SW. Routine staging laparoscopy has no place in the management of colorectal liver metastases. <i>Eur J Surg Oncol.</i> 2013;39(7):721-5.	2013	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific and outside the scope of the guideline.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Stättner S, Jones RP, Yip VS, Buchanan K, Poston GJ, Malik HZ, Fenwick SW. Microwave ablation with or without resection for colorectal liver metastases. <i>Eur J Surg Oncol.</i> 2013;39(8):844-9.	2013	22/11/2017	Ongoing	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Jones RP, Sutton P, Greensmith RM, Santoyo-Castelazo A, Carr DF, Jenkins R, Rowe C, Hamlett J, Park BK, Terlizzo M, O'Grady E, Ghaneh P, Fenwick SW, Malik HZ, Poston GJ, Kitteringham NR. Hepatic activation of Irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI; exploratory findings from a phase II study. <i>Cancer Chemother Pharmacol</i> . 2013;72(2):359-68	2013	22/11/2017	Ongoing	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Grunhagen DJ, Dunne DF, Sturgess RP, Stern N, Hood S, Fenwick SW, Poston GJ, Malik HZ. Metal stents: a bridge to surgery in hilar cholangiocarcinoma. <i>HPB</i> 2013; 15(5): 372-378.	2013	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Jones RP, Stättner S, Dunne DF, O'Grady E, Smethurst A, Terlizzo M, Malik HZ, Fenwick SW, Poston GJ. Radiological assessment of response to neoadjuvant transcatheter hepatic therapy with irinotecan-eluting beads (DEBIRI®) for colorectal liver metastases does not predict tumour destruction or long-term outcome. <i>Eur J Surg Oncol.</i> 2013 Oct;39(10):1122-8.	2013	22/11/2017	Ongoing	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Yip VS, Gomez D, Tan CY, Staettner S, Terlizzo M, Fenwick S, Malik HZ, Ghaneh P, Poston G. Tumour size and differentiation predicts survival after liver resection for hepatocellular carcinoma arising in non-cirrhotic and non-fibrotic liver. <i>Int J Surg.</i> 2013;11(10):1078-82	2013	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Jones RP, Dunne D, Sutton P, Malik HZ, Fenwick SW, Terlizzo M, O'Grady E, Koelblinger C, Stättner S, Stremitzer S, Gruenberger T, Poston GJ. Segmental and lobar administration of drug-eluting beads delivering irinotecan leads to tumour destruction: a case-control series. <i>HPB</i> . 2013 Jan;15(1):71-7.	2013	22/11/2017	Ongoing	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Evrard S, Poston G, Kissmeyer-Nielsen P, Diallo A, Desolneux G, Brouste V, Lalet C, Mortensen F, Stättner S, Fenwick S, Malik H, Konstantinidis I, DeMatteo R, D'Angelica M, Allen P, Jarnagin W, Mathoulin-Pelissier S, Fong Y. Combined ablation and resection (CARE) as an effective parenchymal sparing treatment for extensive colorectal liver metastases. <i>PLoS One</i> . 2014; 9(12): e114404	2014	22/11/2017	Ongoing	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Yip VS, Collins B, Dunne DF, Koay MY, Tang JM, Wieshmann H, Fenwick SW, Poston GJ, Malik HZ. Optimal imaging sequence for staging in colorectal liver metastases: analysis of three hypothetical imaging strategies. <i>Eur J Cancer</i> . 2014 Mar;50(5):937-43.	2014	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Dunne DFJ, Jones RP, Malik HZ, Fenwick SW, Poston GJ. Surgical management of colorectal liver metastases: a European perspective. <i>Hepatic Oncol</i> .2014; 1(1): 121- 133	2014	22/11/2017	Ongoing	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Gomez D, Wetherill C, Cheong J, Jones L, Marshall E, Damato B, Coupland SE, Ghaneh P, Poston GJ, Malik HZ, Fenwick SW. The Liverpool uveal melanoma liver metastases pathway: outcome following liver resection. <i>J Surg Oncol.</i> 2014 May;109(6):542-7.	2014	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Stättner S, Yip V, Jones RP, Lacasia C, Fenwick SW, Poston GJ, Malik H. Liver resection with concomitant inferior vena cava resection: experiences without veno- venous bypass. <i>Surg Today.</i> 2014 Jun;44(6):1063-71	2014	22/11/2017	Ongoing	Declare and participate. Rationale: interest is non-specific

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Jones RP, Stättner S, Sutton P, Dunne DF, McWhirter D, Fenwick SW, Malik HZ, Poston GJ. Controversies in the oncosurgical management of liver limited stage IV colorectal cancer. <i>Surg Oncol.</i> 2014 Jun;23(2):53-60	2014	22/11/2017	Ongoing	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Dunne DF, Yip VS, Jones RP, McChesney EA, Lythgoe DT, Psarelli EE, Jones L, Lacasia-Purroy C, Malik HZ, Poston GJ, Fenwick SW. Enhanced recovery in the resection of colorectal liver metastases. <i>J Surg Oncol.</i> 2014 Aug;110(2):197-202	2014	22/11/2017	Ongoing	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee				Publication Date: 29 January 2020			
Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Jones RP, Hamann S, Malik HZ, Fenwick SW, Poston GJ, Folprecht G. Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. <i>Eur J Cancer</i> . 2014;50(9):1590- 601.	2014	22/11/2017	Ongoing	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Yip VS, Poston GJ, Fenwick SW, Wiesmann H, Athwal T, Malik HZ. FDG-PET-CT is effective in selecting patients with poor long term survivals for colorectal liver metastases. <i>Eur J Surg Oncol</i> . 2014 Aug;40(8):995-9	2014	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific and outside the scope of the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee				Publication Date: 29 January 2020			
Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Dunne DF, Jones RP, Lythgoe DT, Pilkington FJ, Palmer DH, Malik HZ, Poston GJ, Lacasia C, Jack S, Fenwick SW. Cardiopulmonary exercise testing before liver surgery. <i>J Surg Oncol</i> . 2014 Sep;110(4):439-44.	2014	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific and outside the scope of the guideline.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Stättner S, Primavesi F, Yip VS, Jones RP, Öfner D, Malik HZ, Fenwick SW, Poston GJ. Evolution of surgical microwave ablation for the treatment of colorectal cancer liver metastasis: review of the literature and a single centre experience. <i>Surg Today</i> . 2015;45(4):407-15	2015	22/11/2017	Ongoing	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Evans JP, Sutton PA, Winiarski BK, Fenwick SW, Malik HZ, Vimalachandran D, Tweedle EM, Costello E, Palmer DH, Park BK, Kitteringham NR. From mice to men: Murine models of colorectal cancer for use in translational research. <i>Crit Rev Oncol Hematol.</i> 2016;98:94-105.	2016	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Dunne DF, Jack S, Jones RP, Jones L, Lythgoe DT, Malik HZ, Poston GJ, Palmer DH, Fenwick SW. Randomized clinical trial of prehabilitation before planned liver resection. <i>Br J Surg.</i> 2016;103(5):504-12.	2016	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Yip VS, Dunne DF, Samuels S, Tan CY, Lacasia C, Tang J, Burston C, Malik HZ, Poston GJ, Fenwick SW. Adherence to early mobilisation: Key for successful enhanced recovery after liver resection. <i>Eur J Surg Oncol.</i> 2016; 42(10):1561-1567.	2016	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Jones RP, Malik HZ, Fenwick SW, Terlizzo M, O'Grady E, Stremitzer S, Gruenberger T, Rees M, Plant G, Figueras J, Albiol M, Adam R, Awad S, Poston GJ. PARAGON II - A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer. Eur J Surg Oncol. 2016 Aug 10 [Epub ahead of print]	2016	22/11/2017	Ongoing	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Diaz-Nieto R, Fenwick S, Malik H, Poston G. Defining the Optimal Use of Ablation for Metastatic Colorectal Cancer to the Liver Without High-Level Evidence. Curr Treat Options Oncol. 2017 Feb;18(2):8	2017	22/11/2017	Ongoing	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Fenwick SW and Dasgupta D. (2010). Benign Cystic Disease of the Liver. In: Poston G, D'Angelica M, Adam R Surgical Management of Hepatobiliary and Pancreatic Disorders. 2nd ed. London: Informa. 301-308.	2010	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, non-financial	Satchidanand R, Fenwick SW, Malik HZ (2010). Resection for hepatocellular carcinoma. In: Poston G, D'Angelica M, Adam R Surgical Management of Hepatobiliary and Pancreatic Disorders. 2nd ed. London: Informa. 192-197.	2010	22/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, financial	Funded to attend ECIO conference and paid honorarium to lead session on DEBIRI beads	24/04/2018	18/12/2018	26/04/2018	Declare and participate. Rationale: Interest is specific to the review question about management of colorectal liver metastases, however, no recommendations were made about DEBIRI.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Indirect, financial	Principle Investigator for PHP-301 (FOCUS) trial of Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma. Funding received for department.	February 2019	24/04/2019	Ongoing	Declare and participate. Rationale: Rationale: Interest is non-specific.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Indirect, financial	Principle Investigator for EMT2 trial - A randomised placebo-controlled phase III trial of the effect of the omega-3 fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases. Funding received for department.	April 2019	24/04/2019	Ongoing	Declare and participate. Rationale: Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Indirect, financial	Principle Investigator for PURASTAT trial - Post-Market Clinical Study to Confirm Safety and Performance of PuraStat Absorbable Haemostatic Material for the Management of Bleeding in Liver Surgery. Funding received for department.	February 2019	24/04/2019	On going	Declare and participate. Rationale: Interest is non-specific.
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Direct, financial	Invited speaker to Russian Oncology Conference (sponsored by Merck) on June 21 st 2019 The talk is on the topic of downsizing to resectability in the management of colorectal cancer liver metastases. This topic has not been specifically covered in the guideline.	20/06/ 2019	24/04/2019	23/06/2019	Declare and participate. Rationale: Interest is non-specific as downsizing of liver metastases was not covered in this guideline.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Gemma Burgess	Co-opted committee member (Dietitian)	Direct, financial	My post is currently funded by Macmillan until July 2018.	Oct 2016	15/11/2017	July 2018	Declare and participate. Rationale: Interest is non-specific.
Gemma Burgess	Co-opted committee member (Dietitian)	Direct, financial	Has taken a new role from July 2018 with University Hospitals Coventry & Warwickshire NHS Trust.	July 2018	04/07/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Ratan Verma	Co-opted committee member (Radiologist)	Direct, financial	Private practice radiology declared, less than 5%, private practice mirrors NHS practice.	2003	06/02/2018	Ongoing	Declare and participate. Rationale: Private practice mirrors entirely his NHS practice and constitutes only 5% of his patients
Richard Roope	Committee member (GP)	Direct, financial	Cancer role (remunerated) with the RCGP	Apr 2014	09/09/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Richard Roope	Committee member (GP)	Direct, financial	Cancer role (remunerated) with Cancer Research UK.	Jul 2015	09/09/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Richard Roope	Committee member (GP)	Direct, financial	Director of Hampshire Occupational Health LTD.	2011	15/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Richard Roope	Committee member (GP)	Direct, financial	<p>Paid for guest speaking at 2 Bowel Cancer UK Education Update events for a cross section of Clinicians. The talks were titled:</p> <p>"Lifestyle and colorectal cancer prevention" (18.9.14)</p> <p>"Colorectal cancer: Assessing Symptoms – when to refer" (9.11.16)</p> <p>Honoraria paid.</p>	18/09/2014 & 09/11/2016	15/11/2017	18/09/2014 & 09/11/2016	<p>Declare and participate.</p> <p>Rationale: Interest is non-specific.</p>
Richard Roope	Committee member (GP)	Direct, non-financial	A strategic vision for cancer – Wessex Cancer Strategic Clinical Network (Sections on Prevention and Early Diagnosis)	2016	15/11/2017	2016	<p>Declare and participate.</p> <p>Rationale: Interest is non-specific.</p>

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Richard Roope	Committee member (GP)	Direct, non-financial	Benton SC, Butler P, Allen K, Chesters M, Rickard S, Stanley S, Roope R, Vulkan D, Duffy SW. GP participation in increasing uptake in a national bowel cancer screening programme: the PEARL project. <i>British journal of cancer</i> . 2017 Jun 6;116(12):1551.	2017	15/11/2017	Ongoing	Declare and participate. Rationale: Interest is non-specific as screening is outside the scope of the guideline.
Richard Roope	Committee member (GP)	Direct, non-financial	Invited to join the Clinical Advisory Panel at Cancer Research UK. Role started in May 2018.	May 2018	03/05/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Richard Roope	Committee member (GP)	Direct, non-financial	Scientific Board for Oncimmune (Oncimmune Holdings PLC profiles the body's immune response to detect cancers earlier)	05/12/2018	18/12/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Richard Roope	Committee member (GP)	Direct non-financial	Member of RCGP Quality Outcome Framework (QOF) Quality Improvement Advisory Group	18 April 2019	24/04/2019	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Charlotte Dawson	Committee member (Colorectal Clinical Nurse Specialist)	Direct, non-financial	Committee member of the Association of Coloproctology Nurse Group.	2018	10/01/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Charlotte Dawson	Committee member (Colorectal Clinical Nurse Specialist)	Direct, financial	<p>I currently work 3 days a week (salaried) for the Charity Beating Bowel Cancer. This charity has just announced its merger with the charity Bowel Cancer UK.</p> <p>I receive no funding for my role from any external agency.</p> <p>Aside from providing information about the nurse advisory service, its role and remit as part of a grant application process I am not involved in obtaining or approving grants or donations made to the charity.</p>	Jan 2016	10/01/2018	Ongoing	<p>Declare and participate.</p> <p>Rationale: Interest is non-specific.</p>

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Michael Braun	Committee member (Oncologist)	Direct, non-financial	Co-lead of the National Bowel Cancer Audit Project	2016	Nov 2017	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Michael Braun	Committee member (Oncologist)	Direct, financial	<p>Payments for Servier and Amgen for delivering talks at regional educational meetings.</p> <p><u>Servier</u> Talk on 7th Dec 2017: Overview of the chemotherapy options for advanced colorectal cancer. Not specific to any drug. Payment from Servier to be received in Jan 2018.</p> <p>Chaired a meeting which other people spoke at. The talks covered: Trifluridine data, adjuvant chemotherapy for bowel cancer, stereotactic ablative radiotherapy, and managing stress at work.</p> <p><u>Amgen</u> Talk on May 2017: A comparison of the treatment time and costs of cetuximab and panitumumab in a model based on the practice at the Christie. Payment received on June 2017.</p>	2017	02/01/2018	2018	<p>Declare and participate.</p> <p>Rationale: Recommending specific systemic therapy drugs are outside the scope of this guideline. Talk funded by Servier not specific to any drug. Talk funded by Amgen related to cetuximab and panitumumab which are covered by NICE technology appraisals and not by this guideline.</p>
Michael Braun	Committee member (Oncologist)	Direct, financial	Travel and accommodation at World GI conference provided by Amgen in July 2017	July 2017	02/01/2018	July 2017	Declare and participate.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
			A 1,000 article was written for Amgen about the highlights of the conference which was circulated internally (Amgen) as part of a newsletter.				Rationale: Interest is non-specific.

Michael Braun	Committee member (Oncologist)	Indirect, financial	<p>Local Principal Investigator for FOXTROT (Fluoropyrimidine, Oxiliplatin and Targeted-Receptor pre-Operative Therapy for patients with high-risk, operable colon cancer) chemical trial.</p> <p>Department received funding for recruitment of participants for the study.</p>	May 2009	02/01/2018	Ongoing	<p>Declare and participate.</p> <p>Rationale: The trial is relevant for review 3.3 on preoperative therapy for colon cancer, however, as a local principal investigator the committee member did not receive funding (the trial was funded by Cancer Research UK) or was not involved in the planning of the trial, or the analysis and write up of the results.</p>
---------------	-------------------------------	---------------------	--	----------	------------	---------	--

Michael Braun	Committee member (Oncologist)	Indirect, financial	<p>Local Principal Investigator for SCOT (Short Course Oncology Treatment) chemical trial – a study of adjuvant chemotherapy in colorectal cancer by the CACTUS and OCTO groups. The main aim of the study is to assess the difference in disease-free survival for patients receiving either 12 weeks or 24 weeks of chemotherapy for colorectal cancer.</p> <p>Department received funding for recruitment of participants for the study.</p>	May 2009	02/01/2018	Ongoing	<p>Declare and participate.</p> <p>Rationale: The trial is relevant for review 3.7 on duration of adjuvant chemotherapy, however, as a local principal investigator the Committee member did not receive funding (the trial was funded by Medical Research Council, Swedish Cancer Society, NETSCC, and Cancer Research UK) or was not involved in the planning of</p>
---------------	-------------------------------	---------------------	---	----------	------------	---------	--

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
							the trial, or the analysis and write up of the results.
Michael Braun	Committee member (Oncologist)	Direct, financial	Attending the European Society of Medical Oncology 2018 meeting supported by Servier. Servier will provide flights, accommodation and conference registration fees, no direct or paid work involved.	2018	23/04/2018	2018	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Michael Braun	Committee member (Oncologist)	Indirect, financial	<p>Working on a trial as Chief Investigator. The study will take place at 3 UK centres (Christie, Bournemouth and Poole) and will randomise 60 1st-line, RAS wild-type colorectal cancer patients. The trial gives standard chemotherapy plus placebo or an investigational drug. The study will be funded by UK Merck (5%) and Xbiotech (95% funding, who manufacture the investigational drug). Department receives funding. Michael does not receive any personal payments for this work.</p> <p>The management of RAS wild-type colorectal cancer isn't a question in the NICE review as there has recently been a technology appraisal which defines the optimal treatment.</p>	2018	22/08/2018	Ongoing	<p>Declare and participate.</p> <p>Rationale: Interest is non-specific, the management of RAS wild-type colorectal cancer isn't a question in the guideline as there has recently been a technology appraisal which defines the optimal treatment.</p>

Michael Braun	Committee member (Oncologist)	Direct, non-financial	Co-chairing an update in colorectal cancer day in Manchester organised by Servier UK. Giving a talk about his involvement in National Bowel Cancer Audit. Not chairing topic areas covered in this guideline. No personal payment taken.	22/11/2019	02/10/2019	22/11/2019	Declare and participate. Rationale: Agreed that the member will not chair any sessions related to topics covered by guideline, will not comment and express opinions about any topic covered by this guideline, will not take personal payment for this activity.
Cindy Chew	Committee member (Radiologist)	Direct, non-financial	Standards Officer – British Society of Gastrointestinal and Abdominal Radiology. Role started Feb 2018.	Feb 2018	19/04/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Cindy Chew	Committee member (Radiologist)	Direct, non-financial	Honorary Secretary – Scottish Radiological Society. Role started Nov 2017.	Nov 2017	19/04/2018	Ongoing	Declare and participate.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
							Rationale: Interest is non-specific.
Cindy Chew	Committee member (Radiologist)	Indirect, financial	Local PI – TRIGGER Using the magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify between good and poor responders following chemoradiotherapy in rectal cancer: a multicentre randomised control trial. Funding received by Hairmyres Hospital.	2017	01/05/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific, the topic is outside the scope of the guideline.
Cindy Chew	Committee member (Radiologist)	Direct, financial	Hospital Sub-Dean for Glasgow University and Hairmyres Hospital.	01/09/2018	19/12/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Cindy Chew	Committee member (Radiologist)	Indirect, non-financial	Early Cancer Detection Test – Lung Cancer Scotland (ECLS) – NCT01925625 (Oncimmune) Sponsor: NHS Scotland. 12000 patients. I am one of several radiologists across Scotland who read the CTs of the intervention arm of patients with positive blood test. Funding was given directly to the Trust.	2016	21/03/2019	2019	Declare and participate. Rationale: Interest is non-specific.
Cindy Chew	Committee member (Radiologist)	Direct, financial	Hospital Sub-Dean for Glasgow University and Hairmyres Hospital	Feb 2019	24/04/2019	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Manuel Salto-Tellez	Co-opted committee member (Molecular Pathologist)	Direct, financial	Scientific Advisor of Philips Computational. Advises them on general applications on biomarker analysis (pathology) – breast, lung, melanoma. Not specific to CRC. Received honoraria on monthly.	Jan 2017	22/01/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Manuel Salto-Tellez	Co-opted committee member (Molecular Pathologist)	Direct, financial	Advisory Board for Visiopharm. Computational. Advises them on general applications on biomarker analysis (pathology) – breast. Not specific to CRC. Expenses paid.	Jan 2015	22/01/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Manuel Salto-Tellez	Co-opted committee member (Molecular Pathologist)	Direct, financial	Ad-hoc advisory board for pharma and biotech companies. Molecular pathology in general and digital pathology. There has been honoraria paid for most of the occasions. Companies include: Roche, MSD, Az (pharma company). Not specific to CRC.	Mar 2011	22/01/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Manuel Salto-Tellez	Co-opted committee member (Molecular Pathologist)	Direct, financial	Ad-hoc lectures with honoraria organized by pharma and biotech companies. Molecular pathology in general and digital pathology. Honoraria has been paid sometimes and expenses always paid. Not specific to CRC.	Mar 2011	22/01/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Manuel Salto-Tellez	Co-opted committee member (Molecular Pathologist)	Direct, non-financial	I am part of the S-CORT research programme, which will eventually analyse samples from the FOxTROT trial. I can confirm that no such samples have been analysed in my laboratory to date.	2009	22/03/2019	Ongoing	Declare and participate. Rationale: FOxTROT trial relates to review question 3.3 on neoadjuvant therapy on colon cancer but the programme is not specific to the review question.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Manuel Salto-Tellez	Co-opted committee member (Molecular Pathologist)	Indirect, financial	<p>Co PI in a project to develop a test in colorectal cancer to score immune biomarkers of prognosis.</p> <p>This is supported by a mixture of government funding (Innovate UK) and industry (Philips).</p> <p>If successful, Philips will have first-right to buy this product from us. The benefits will go back to the NHS.</p> <p>No personal payment goes to Salto-Tellez or other members of this programme in relation to this activity.</p>	July/Aug 2019	24/04/2019	N/A	<p>Declare and participate.</p> <p>Rationale: Interest is non-specific and outside the scope of this guideline.</p>

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Michael Shackcloth	Co-opted member (Thoracic Surgeon)	Direct, financial	Perform pulmonary metastasectomy privately (income approximately £2000 per year)	2014	08/07/2018	Ongoing	Declare and participate. Rationale: Private practice mirrors work in the NHS and constitutes a small proportion of his work.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Michael Shackcloth	Co-opted member (Thoracic Surgeon)	Indirect, financial	Principle investigator at Liverpool Heart and Chest Hospital for the PulMiCC trial. The trial ended in 2017. Funding to department.	2013	08/07/2018	2017	Declare and participate. Rationale: This paper did not feature as evidence in the guideline.
Michael Shackcloth	Co-opted member (Thoracic Surgeon)	Indirect, financial	Co-investigator on a neo-adjuvant TKI study in lung cancer funded by Astra-Zenica	March 2019	24/04/2019	Ongoing	Declare and participate. Rationale: The interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Faheez Mohamed	Co-opted member (Peritoneal specialist)	Direct, non-financial	Member Association of Coloproctology of GB and I (ACPGBI) Research and Audit Committee	2014	01/12/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Faheez Mohamed	Co-opted member (Peritoneal specialist)	Direct, non-financial	Member Association of Surgeon of GB and I Scientific committee	2013	01/12/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.
Faheez Mohamed	Co-opted member (Peritoneal specialist)	Direct, non-financial	Trustee Pelican Cancer Foundation	2015	01/12/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Faheez Mohamed	Co-opted member (Peritoneal specialist)	Direct, non-financial	Editorial Board, Pleura and Peritoneum	2016	01/12/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Faheez Mohamed	Co-opted member (Peritoneal specialist)	Direct, financial	<p>Undertakes private practice at BMI Hampshire Clinic and North Hampshire Hospital Basingstoke treating patients with all colorectal conditions, including those with colorectal cancer.</p> <p>Faheez's private practice entirely mirrors NHS practice, e.g. diagnoses and treats patients with colorectal cancer in NHS and private practice as part of a MDT. Receives payment for private practice, as for NHS practice. Paid on a 'fee per service' basis.</p> <p>Faheez spends approximately 30% of his time managing private patients of which 5% have colorectal cancer. Private patients and NHS patients are treated identically.</p>	2010	01/12/2018	Ongoing	<p>Declare and participate.</p> <p>Rationale: Private practice mirrors the work in the NHS and private CRC patients constitutes 5% of his workload.</p>

Interests Register

Note:

Interests declared up to and including 31st March 2018 were processed under the 2014 NICE policy on conflicts of interest.

Interests declared from 1st April 2018 were processed under the 2018 NICE policy on conflicts of interest.

Colorectal Cancer (update) Guideline Committee

Publication Date: 29 January 2020

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments GL=guideline lead
				Interest arose	Interest declared	Interest ceased	
Faheez Mohamed	Co-opted member (Peritoneal specialist)	Indirect, financial	Co-applicant Bowel Disease Research Foundation funded IDEAL-PM study. Faheez did not receive any personal funding for this.	2016	01/12/2018	Ongoing	Declare and participate. Rationale: Interest is non-specific.